Phospho-FRS2 (Tyr436) Antibody

What is FRS2 and what role does phosphorylation at Tyrosine 436 play in cellular signaling?

FRS2 (Fibroblast growth factor receptor substrate 2) is a 57 kDa adaptor protein that links activated fibroblast growth factor (FGF) and nerve growth factor (NGF) receptors to downstream signaling pathways. The FRS2 family comprises two members, FRS2-α and FRS2-β, both containing an amino-terminal myristoylation signal, a phosphotyrosine binding domain, and a carboxy-terminal tail with adaptor protein binding domains .

Phosphorylation at Tyrosine 436 is particularly important as this site recruits SHP-2 signaling proteins, while another phosphorylation site at Tyr196 interacts with GRB-SOS signaling complexes . When the FGF receptor binds its ligand, it undergoes autophosphorylation, leading to FRS2 binding, subsequent phosphorylation, and recruitment of SHP2 and GRB2. This complex then binds GAB1, activates PI3K, and converts PIP2 to PIP3, resulting in AKT translocation to the plasma membrane and downstream signaling through pathways involving GSK-3β, FOX01, and FOX03 .

What are the key structural components and biological functions of FRS2?

FRS2 consists of several key structural domains:

• An amino-terminal myristoylation signal

• A phosphotyrosine binding (PTB) domain

• A carboxy-terminal tail containing adaptor protein binding domains

The phosphotyrosine binding domains of FRS2-α and FRS2-β interact directly with fibroblast and nerve growth factor receptors in both phosphorylation-dependent and phosphorylation-independent manners . FRS2 modulates signaling via SHC1 by competing for a common binding site on NTRK1 and plays critical roles in:

• Linking FGF and NGF receptors with the RAS/MAPK signaling pathways

• Activating MAP kinases

• Facilitating phosphorylation of PIK3R1 (the regulatory subunit of phosphatidylinositol 3-kinase)

• Contributing to the PI3-Kinase/Akt pathway

What are the optimal conditions for detecting phosphorylated FRS2 at Tyr436 using Western blotting?

For optimal detection of phosphorylated FRS2 at Tyr436 using Western blotting, researchers should follow these guidelines:

• Sample preparation:

  • Use freshly prepared cell lysates due to the unstable nature of phosphoproteins

  • Discard any unused thawed material to maintain phosphoprotein integrity

  • Avoid buffers containing phosphate when detecting phosphoproteins

• Dilution and protocol:

  • Use a dilution ratio of 1:500-1:2000 for Western blotting applications

  • For Cell Signaling Technology antibody: use a 1:1000 dilution

• Positive controls:

  • NIH3T3 cells treated with FGF (100 ng/mL; 5 minutes)

  • MCF-7 human breast cancer cell line treated with 100 μM pervanadate for 10 minutes

  • PC-12 rat adrenal pheochromocytoma cell line treated with 100 ng/mL Recombinant Rat beta-NGF for 10 minutes

• Expected molecular weight:

  • Look for bands at approximately 70-90 kDa or 80-85 kDa

• Experimental conditions:

  • Conduct experiments under reducing conditions

  • Use appropriate immunoblot buffer groups (e.g., Immunoblot Buffer Group 1)

What standardized protocol is recommended for the MULTI-ARRAY Phospho-FRS2 (Tyr436) Assay?

The MULTI-ARRAY Phospho-FRS2 (Tyr436) Assay involves a sandwich immunoassay format with the following standardized protocol:

Step 1: Block Plate and Prepare Sample

• Add 150 μL/well of blocking solution

• Incubate at room temperature with vigorous shaking (300–1000 rpm) for 1 hour

• Prepare complete lysis buffer just prior to sample dilution

• Prepare positive and negative cell lysates and keep on ice until use

Step 2: Wash and Add Sample

• Wash the plate 3 times with 300 μL/well of Tris Wash Buffer

• Dispense 25 μL/well of sample

• Incubate at room temperature with vigorous shaking (300–1000 rpm) for 3 hours

Step 3: Wash and Add Detection Antibody Solution

• Wash the plate 3 times with 300 μL/well of Tris Wash Buffer

• Dispense 25 μL/well 1X detection antibody solution

• Incubate at room temperature with vigorous shaking (300–1000 rpm) for 1 hour

Step 4: Wash and Read Plate

• Wash the plate 3 times with 300 μL/well of Tris Wash Buffer

• Dispense 150 μL/well 1X Read Buffer T

• Analyze plate on SECTOR Imager within 5 minutes of read buffer addition

How do I interpret lysate titration data for the Phospho-FRS2 (Tyr436) Assay?

The interpretation of lysate titration data requires understanding the signal-to-noise ratio and variability in measurements. Below is a representative table showing lysate titration data for positive and negative NIH3T3 cell lysates:

When interpreting this data:

• Signal increase with titration: Note that positive lysate signals increase substantially with higher lysate concentrations, while negative lysate signals remain relatively low throughout the titration

• Positive/Negative (P/N) ratio: The P/N ratio indicates the assay's sensitivity and specificity - ratios of 5-10 indicate good discrimination between positive and negative samples

• Coefficient of variation (%CV): Lower %CV values indicate better reproducibility and precision; most values in this dataset show good reproducibility (under 10%)

How do Western blot and immunoassay results for Phospho-FRS2 (Tyr436) compare in terms of sensitivity and specificity?

When comparing Western blot and immunoassay methodologies for detecting Phospho-FRS2 (Tyr436):

Western Blot Analysis:

• Provides qualitative or semi-quantitative data with visual band detection

• Typically requires more sample material

• Can demonstrate specificity by showing a single band at the expected molecular weight (80-85 kDa)

• Allows visualization of potential non-specific binding

• Less sensitive for quantification compared to immunoassay methods

MSD MULTI-ARRAY Phospho-FRS2 (Tyr436) Assay:

• Provides quantitative data with precise numerical values

• Requires smaller sample volumes

• Higher throughput capability with 96-well plate format

• Greater sensitivity for detecting phosphorylation changes

• More reproducible with lower %CV values

• Provides a more powerful tool to generate reproducible and reliable results

Comparative studies show that the MULTI-ARRAY Phospho-FRS2 (Tyr436) Assay provides a quantitative measure of the data obtained with traditional Western blot, offering enhanced sensitivity and reproducibility while maintaining specificity .

What are common issues encountered when using Phospho-FRS2 (Tyr436) Antibody in Western blotting and how can they be resolved?

What are the limitations of no-wash assay formats for detecting Phospho-FRS2 (Tyr436)?

While no-wash assay formats offer convenience and reduced processing steps, they come with several limitations for Phospho-FRS2 (Tyr436) detection:

For optimal results with Phospho-FRS2 (Tyr436) detection, the standard protocol with appropriate washing steps is recommended, particularly for samples with low phosphorylation levels or complex matrices .

How can Phospho-FRS2 (Tyr436) Antibody be used to investigate FGF/FGFR signaling in cancer research?

The FGF/FGFR signaling cascade is believed to play significant roles in many different types of human cancers, making it an active area of pharmaceutical research . Researchers can utilize Phospho-FRS2 (Tyr436) Antibody in cancer research through several approaches:

• Pathway activation analysis: Monitor FRS2 Tyr436 phosphorylation as a direct indicator of FGFR pathway activation in cancer cell lines and tumor samples

• Drug screening and development:

  • Evaluate the efficacy of FGFR inhibitors by measuring changes in FRS2 phosphorylation

  • Use as a pharmacodynamic biomarker for targeted therapies affecting the FGF/FGFR signaling cascade

• Resistance mechanism studies:

  • Investigate whether altered FRS2 phosphorylation contributes to resistance against targeted therapies

  • Examine bypass signaling pathways that maintain FRS2 phosphorylation despite FGFR inhibition

• Combination therapy assessment:

  • Measure the impact of combining FGFR inhibitors with other targeted agents on FRS2 phosphorylation

  • Identify optimal drug combinations that more effectively suppress this signaling node

• Biomarker development:

  • Correlate FRS2 Tyr436 phosphorylation levels with clinical outcomes

  • Develop tissue-based or liquid biopsy assays for patient stratification

The antibody can be applied in multiple experimental platforms including Western blotting, immunohistochemistry, and quantitative immunoassays to comprehensively map FRS2 phosphorylation patterns in cancer research contexts .

What are the considerations for studying cross-talk between FRS2-mediated signaling and other pathways?

When investigating cross-talk between FRS2-mediated signaling and other pathways, researchers should consider:

• Temporal dynamics of phosphorylation:

  • FRS2 phosphorylation at different sites (Tyr436 vs. Tyr196) may occur with different kinetics

  • Design time-course experiments to capture early, intermediate, and late phosphorylation events

• Multiple pathway activation markers:

  • Simultaneously monitor phosphorylation of FRS2 at Tyr436 alongside other pathway components

  • Consider multiplex assays or parallel Western blots for AKT, ERK, and other signaling molecules

• Inhibitor specificity challenges:

  • Use multiple independent inhibitors targeting the same pathway to confirm observations

  • Employ genetic approaches (siRNA, CRISPR) to validate findings from pharmacological studies

• Cell type-specific signaling networks:

  • FRS2 signaling may vary significantly between cell types

  • Compare results across multiple relevant cell lines or primary samples

• Context-dependent pathway interactions:

  • The interaction between FRS2 and other pathways may depend on cellular stress, nutrient availability, or microenvironment

  • Design experiments that account for these contextual factors

• Technical considerations for phospho-specific detection:

  • Use both phospho-specific antibodies (like Phospho-FRS2 Tyr436) and total protein antibodies

  • Calculate phospho/total protein ratios for more accurate pathway activation assessment

  • Consider phosphatase inhibitor cocktails during sample preparation to preserve phosphorylation status

What is the documented species reactivity of different Phospho-FRS2 (Tyr436) antibodies, and how has this been validated?

Different manufacturers offer Phospho-FRS2 (Tyr436) antibodies with varying species reactivity profiles:

Validation has been performed through various methods:

• Western blot analysis using:

  • NIH3T3 cells treated with FGF (100 ng/mL; 5 minutes)

  • MCF-7 human breast cancer cells treated with pervanadate

  • PC-12 rat adrenal pheochromocytoma cells treated with NGF

• Immunocytochemistry using:

  • A431 human epithelial carcinoma cell line treated with pervanadate

The antibodies demonstrate specificity by detecting phosphorylated protein only in stimulated samples while showing minimal binding in unstimulated controls .

How can researchers validate antibody specificity for Phospho-FRS2 (Tyr436) in their specific experimental system?

To validate the specificity of Phospho-FRS2 (Tyr436) antibodies in a particular experimental system, researchers should:

• Perform positive and negative control experiments:

  • Positive controls: Treat cells with known activators of FRS2 phosphorylation (FGF, NGF, or pervanadate)

  • Negative controls: Use untreated cells or cells pre-treated with specific inhibitors of FGF/NGF receptors

• Validate molecular weight:

  • Confirm that the detected band appears at the expected molecular weight (80-85 kDa)

  • Note that FRS2 can show slight variations in molecular weight (70-90 kDa) due to post-translational modifications

• Conduct phosphatase treatment:

  • Treat positive control lysates with lambda phosphatase to remove phosphorylation

  • Verify that antibody signal disappears after phosphatase treatment

• Use genetic approaches:

  • Employ FRS2 knockdown or knockout systems to confirm antibody specificity

  • Consider expressing wild-type vs. Y436F mutant FRS2 to validate phospho-site specificity

• Peptide competition assay:

  • Pre-incubate antibody with phospho-peptide and non-phospho-peptide

  • Verify that only the phospho-peptide blocks antibody binding

• Cross-validate with multiple antibodies:

  • Use antibodies from different manufacturers or raised against different epitopes

  • Compare detection patterns to build confidence in specificity

• Mass spectrometry validation:

  • For definitive confirmation, use phospho-enrichment followed by mass spectrometry

  • Identify the specific phosphorylation site directly through peptide sequencing